Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.

NCT07420985 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza
Acute Respiratory Viral Infection

Interventions

DRUG: Ingavirin Forte, 90 mg + 5 mg, Capsules
DRUG: Ingavirin Forte, 90 mg + 10 mg, Capsules
DRUG: Ingavirin Forte, 90 mg + 20 mg, Capsules
DRUG: Ingavirin, 90 mg, Capsules
DRUG: Placebo

Sponsor

Valenta Pharm JSC